Clinical Trial

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Name: Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies — clinical trial record (NCT07486713)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2026-03-17.

Trial Details

NCT Number	NCT07486713
Lead Sponsor	Rigel Pharmaceuticals
Conditions	AML (Acute Myeloid Leukemia), Glioma, Cholangiocarcinoma, Solid Tumor Malignancies
Enrollment	16 participants
Start Date	2026-02-23
Primary Completion	2027-04-30 (estimated)
Study Completion	2027-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-11